Postinfection Irritable Bowel Syndrome

• Published in: Gut and liver Vol. 16; no. 3; pp. 331 - 340
• Main Author: Ghoshal, Uday C
• Format: Journal Article
• Language: English
• Published: Korea (South) Editorial Office of Gut and Liver 01-05-2022; Gastroenterology Council for Gut and Liver; 거트앤리버 소화기연관학회협의회
• Subjects: covid-19; dysentery; enteritis; gastrointestinal disorders; Review; tropical sprue; 내과학; COVID-19; Tropical sprue; Dysentery; Enteritis; Gastrointestinal disorders
• ISSN: 1976-2283; 2005-1212
• DOI: 10.5009/gnl210208

Following acute gastroenteritis (AGE) due to bacteria, viruses, or protozoa, a subset of patients develop new onset Rome criteria positive irritable bowel syndrome (IBS), called postinfection IBS (PI-IBS). The pooled prevalence of PI-IBS following AGE was 11.5%. PI-IBS is the best natural model that suggests that a subset of patients with IBS may have an organic basis. Several factors are associated with a greater risk of development of PI-IBS following AGE including female sex, younger age, smoking, severity of AGE, abdominal pain, bleeding per rectum, treatment with antibiotics, anxiety, depression, somatization, neuroticism, recent adverse life events, hypochondriasis, extroversion, negative illness beliefs, history of stress, sleep disturbance, and family history of functional gastrointestinal disorders (FGIDs), currently called disorder of gut-brain interaction. Most patients with PI-IBS present with either diarrhea-predominant IBS or the mixed subtype of IBS, and overlap with other FGIDs, such as functional dyspepsia is common. The drugs used to treat non-constipation IBS may also be useful in PI-IBS treatment. Since randomized controlled trials on the efficacy of drugs to treat PI-IBS are rare, more studies are needed on this issue.